Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Current Assets: 2017-2024

Historic Current Assets for Protagonist Therapeutics (PTGX) over the last 8 years, with Dec 2024 value amounting to $591.6 million.

  • Protagonist Therapeutics' Current Assets rose 23.00% to $586.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $586.4 million, marking a year-over-year increase of 23.00%. This contributed to the annual value of $591.6 million for FY2024, which is 66.39% up from last year.
  • Per Protagonist Therapeutics' latest filing, its Current Assets stood at $591.6 million for FY2024, which was up 66.39% from $355.6 million recorded in FY2023.
  • Protagonist Therapeutics' 5-year Current Assets high stood at $591.6 million for FY2024, and its period low was $243.1 million during FY2022.
  • Moreover, its 3-year median value for Current Assets was $355.6 million (2023), whereas its average is $396.8 million.
  • As far as peak fluctuations go, Protagonist Therapeutics' Current Assets soared by 117.19% in 2020, and later dropped by 28.66% in 2022.
  • Yearly analysis of 5 years shows Protagonist Therapeutics' Current Assets stood at $315.6 million in 2020, then increased by 7.96% to $340.7 million in 2021, then dropped by 28.66% to $243.1 million in 2022, then surged by 46.28% to $355.6 million in 2023, then soared by 66.39% to $591.6 million in 2024.